Oral Immunoproteasome Inhibitor Program AutoImmune / Inflammatory Diseases

Preclinical

  • Oral therapies that bring the power of proteasome inhibition safely into the field of immunology
  • Developing selective inhibitors of the immunoproteasome subunits to target various autoimmune disorders such as inflammatory bowel diseases (IBD), lupus and psoriasis
  • Selective immunoproteasome inhibition blocks cytokine production and T cell signaling which drives highly pathogenic T-cell populations involved in the initiation of many autoimmune diseases

  • Designed to be devoid of cytotoxicity inherent with pan proteasome drugs